Biotechnology

Ensysce Biosciences Announces Positive Bioequivalence (BE) Study Data of Novel "TAAP" Opioid PF614 and Provides Timing of Corporate Update Call

July 27, 2022 8:05 AM

~ BE Study of PF614 Represents Critical Progress Toward FDA Approval ~ ~ Supports the 505(b)(2) Regulatory Path for Clinical Development of PF614 ~ SAN DIEGO, CA / ACCESSWIRE / July 27, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today the data from the...

Read more

Notice of Annual General Meeting in Biovica International AB

July 27, 2022 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / July 27, 2022 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the annual general meeting on Wednesday 31 August 2022. The board of directors has decided that the annual general meeting shall only be conducted by advance voting (postal voting) on the basis of temporary legislation. Information on...

Read more

Plandai Biotechnology, Inc. Announces Termination of Non-Binding Letter of Intent

July 27, 2022 12:00 AM

SAN DIEGO, CA / ACCESSWIRE / July 27, 2022 / Plandai Biotechnology, Inc. ("Plandai" or the "Company") announces the termination of its non-binding letter of intent dated May 23, 2022, with Ms. Jessie Chiang, license holder of the worldwide rights, exclusive of Taiwan, of the Puriblood Leukocyte Reduction Blood Filtration System. As previously discussed in the Company's May 23, 2022, press release, the Company and Ms. Chiang intended to complete...

Read more

CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing

July 26, 2022 4:45 PM

This press release replaces the press release disseminated July 26, 2022 at 06:00 EDT. The press release contained the wrong image - one intended for a future press release. The corrected press release with the proper image is below: VANCOUVER, BC / ACCESSWIRE / July 26, 2022 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and...

Read more

Black Bird Biotech to Launch National Direct Sales and Secure Distribution Channels for its Grizzly Creek Naturals(TM) CBD Product Line

July 26, 2022 9:10 AM

FLOWER MOUND, TX / ACCESSWIRE / July 26, 2022 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer and distributor of plant-based MiteXstreamTM biopesticide, announced that it will launch an affiliate sales program for its Grizzly Creek NaturalsTM CBD product line in early August 2022. The Company also announced that it is in negotiations to secure distribution for its CBD product line with national reach, with the expectation that a final...

Read more

Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan

July 26, 2022 9:05 AM

KELOWNA, BC / ACCESSWIRE / July 26, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that its exclusive* Japanese Licensee, Premier Wellness Science Co., Ltd., ("Premier") officially launched its first generation of its new cannabidiol ("CBD") products under the brand "Ko", on July 21, 2022 for the Japanese consumer market. Premier will...

Read more

Organicell Announces Matt Sinnreich as CEO

July 26, 2022 7:30 AM

MIAMI, FL / ACCESSWIRE / July 26, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics in the extracellular vesicle space, announced today that the board of directors has appointed Matt Sinnreich as Chief Operating Officer and acting CEO. Sinnreich will replace Mr. Albert Mitrani, the founder of Organicell and CEO since...

Read more

Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing

July 26, 2022 6:00 AM

Independent dermatology research experts at Monasterium Laboratory GmbH tested, analyzed and validated various injection parameters using donated human tissue VANCOUVER, BC / ACCESSWIRE / July 26, 2022 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has now received and analyzed all data and images...

Read more

Apollo Endosurgery to Report Second Quarter Results on August 2, 2022

July 21, 2022 8:00 AM

AUSTIN, TX / ACCESSWIRE / July 21, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the second quarter ended June 30, 2022 on Tuesday, August 2, 2022, after market close. In conjunction with the release, Apollo will host a live...

Read more

Manhattan BioSolutions, Inc. Signs Commercial Evaluation License Agreements with the National Institutes of Health (NIH) for Use of Monoclonal Antibodies in Novel Antibody-Drug Conjugate (ADC) Oncology Programs

July 20, 2022 7:00 AM

NEW YORK, NY / ACCESSWIRE / July 20, 2022 / Manhattan BioSolutions, Inc. today announced it has entered into two commercial evaluation license agreements with the National Cancer Institute (NCI), part of the US National Institutes of Health (NIH), to generate and validate novel antibody-drug conjugate (ADC) therapies using monoclonal antibodies developed by NCI. ADCs harness the targeting ability of antibodies to deliver drugs to the tumor...

Read more

CORRECTION: NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1

July 19, 2022 12:15 PM

This corrects the release that ran earlier today, replacing the name of the executive quoted in the press release and other minor edits. Accelerating on the Path Toward Immunotherapy for Glioblastoma (Brain Cancer) CLEVELAND, OH / ACCESSWIRE / July 19, 2022 / NovAccess Global Inc. (OTC PINK:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the filing of an application with the U.S. Food and...

Read more

Black Bird Biotech Provides Update As Global Concern Over Lasting Effects of Widely-Used Traditional Pesticides on Humans, Wildlife Continues to Rise

July 19, 2022 9:00 AM

FLOWER MOUND, TX / ACCESSWIRE / July 19, 2022 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer and distributor of plant-based MiteXstreamTM biopesticide, confirmed that MiteXstreamTM is now registered in 47 states and D.C., with near-term clearance expected in Florida and Indiana. Initial registration in California is targeted for the first half of 2023. The company also confirmed that it recently began the process for obtaining...

Read more

NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1

July 19, 2022 9:00 AM

Accelerating on the Path Toward Immunotherapy for Glioblastoma (Brain Cancer) CLEVELAND, OH / ACCESSWIRE / July 19, 2022 / NovAccess Global Inc. (OTC PINK:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the filing of an application with the U.S. Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for TLR-AD1, a vaccine immunotherapy for the treatment of aggressive...

Read more

Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent

July 19, 2022 8:00 AM

VERO BEACH, FL / ACCESSWIRE / July 19, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that the United States Patent and Trademark Office (the "USPTO") has issued a Notice of Allowance for claims related to the Company's lead...

Read more

Vitro Biopharma Names Chris Furman Chief Executive Officer

July 18, 2022 1:30 PM

GOLDEN, CO / ACCESSWIRE / July 18, 2022 / Vitro Biopharma Inc. is pleased to announce Chris Furman as Chief Executive Officer and the newest member of the company's Board of Directors. Chris Furman Mr. Furman is a finance industry leader with more than 25 years' experience in private and public capital markets. Chris has a proven track record of hiring and mentoring successful teams while also building strong and lasting relationships at the...

Read more

Roquefort Therapeutics PLC Announces Commencement of Trading on US OTCQB Venture Market

July 15, 2022 2:00 AM

LONDON, UK / ACCESSWIRE / July 15, 2022 / Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to announce that trading in the Company's Ordinary Shares of one pence each ("Ordinary Shares") has commenced on the OTCQB Venture Market in the United States. The Company's OTCQB shares have the ticker: ROQAF There is no associated capital raise with this...

Read more

Biotech Company Expects Preclinical Drug Results on Curing Addiction

July 14, 2022 10:00 AM

ORLANDO, FL / ACCESSWIRE / July 14, 2022 / ACT Sciences (Addiction Cure Therapeutic Sciences Inc) an international Rx solution company targeting drug and alcohol addiction cures and treatments, announced today it expects to receive the results of its first preclinical trial on one of its epigenetic compounds for the treatment of drug addiction within 60 days. Dr. Alex Federation, one of ACT SCIENCES premier scientists and the catalyst for...

Read more

Lexaria To Receive Third Patent Granted in Japan; Submits FDA Filing

July 14, 2022 9:10 AM

KELOWNA, BC / ACCESSWIRE / July 14, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the Company has been notified of the allowance of its 26th worldwide patent with a new patent to be granted in Japan. This is Lexaria's third patent to be granted in Japan, entitled Lipophilic Active Agent Infused Compositions With Reduced Food Effect....

Read more

ENB Therapeutics to Present at SVB Securities Biopharma Private Company Connect on July 20-21, 2022

July 14, 2022 7:00 AM

NEW YORK, NY / ACCESSWIRE / July 14, 2022 / ENB Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics targeting the endothelin B receptor (ETBR) inhibitor, today announced that Sumayah Jamal, MD-PhD, President, Co-Founder, and CSO of ENB Therapeutics, will be participating in the SVB Securities Biopharma Private Company Connect to be held virtually on July 20th and 21st. The ENB team...

Read more

Lexaria's Human Nicotine Study Nearing Start Date

July 13, 2022 9:05 AM

Lexaria is targeting the oral nicotine pouch category, one of the fastest growing segments of the nicotine industry. KELOWNA, BC / ACCESSWIRE / July 13, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the pending start of its upcoming human nicotine study NIC-H22-1. Lexaria expects to evidence that processing purified nicotine with its patented...

Read more